Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose etomidate versus midazolam for prevention of succinylcholine-induced fasciculation
IRCT20160307026950N89Phase 2Recruiting
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of midazolam, etomidate and succinylcholine in Succinylcholine-induced fasciculation (SIF) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Severity of succinylcholine-induced fasciculation. Started Sep 2026; status: recruiting.
02
Drugs
midazolametomidatesuccinylcholine
03
Conditions
Succinylcholine-induced fasciculation (SIF)
Beyond the preview
Go deeper on IRCT20160307026950N89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160307026950N89.